Sanofi India Q4 FY26: Profit & Revenue Decline, Margins Under Pressure

📊 Financial Performance Net Profit: ₹1B vs ₹1.2B YoY (↓17%). Revenue: ₹4.7B vs ₹5.4B YoY (↓13%). EBITDA: ₹1.4B vs ₹1.7B YoY (↓18%). EBITDA Margin: 30.24% vs 32.08% YoY (margin contraction). 📈 Key Financial Ratios Net Profit Margin: ~21.3% (down from ~22.2% YoY). EBITDA Margin: 30.2% (down from 32.1%). ROE: ~12–13% (moderate, impacted by profit decline). ROCE: ~11–12% (reflects weaker capital efficiency). Debt-to-Equity: Very low, Sanofi India operates with a strong balance sheet. Interest Coverage Ratio: High, minimal debt burden. ✅ Fundamentals Global Pharma Backing: Strong parentage under Sanofi Group ensures R&D and product pipeline support. Profitability: Despite decline, margins remain healthy above 30%. Cash Flow Strength: Low leverage and strong liquidity. Product Portfolio: Focus on vaccines, diabetes care, and specialty medicines. Dividend Policy: Historically consistent, though not announced this quarter. ⚠️ Risks & Challenges Revenue Decline: Lower sales impacted by pricing pressure and competition. Margin Contraction: Rising input and compliance costs. Regulatory Risks: Pharma sector faces strict norms on pricing and approvals. Competition: Intense rivalry from domestic and multinational pharma companies. Patent & Pipeline Risks: Dependence on new launches and regulatory clearances.